Agile Therapeutics, Inc. announced today the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch.
Twirla is now available in the U.S. by prescription fro women of reproductive potential with a body mass index (BMI) ,30 kg/m2.
“We are thrilled to launch our first commercial product, Twirla, an effective, modern contraceptive option, for women and their healthcare providers,” said Al Altomari, Chairman and Chief Executive Officer of Agile. “Family planning experts believe the most successful contraception for a woman is one of her choosing that fits her lifestyle, and we believe Twirla will be a valuable addition to the category’s available options. We are committed to seeking ways to make Twirla affordable and accessible for women.”
Twirla is worn weekly and delivers a 30-mcg daily dose of ethinyl estradiol, along with a 120 mcg daily dose of levonorgestrel. Twirla is designed to be worn on the abdomen, buttock, or upper torso (excluding the breasts). At less than 1mm thin, Tqirla is made up of five distinct layers for focused drug delivery to help maintain adhesion.
For more information, visit Twirla.com.